Home > Back to Publisher > Report Information

Global Markets for Antifungal Agents

BCC Research
March 30, 2007
133 Pages - SKU: WA1484498

Abstract Table of Contents Related Reports

Countries covered: Global

This report contains: An examination of the major markets for antifungal applications in human healthcare, veterinary healthcare, agriculture and the environment/buildings; Analysis of each market segment on the global level, with current market status, and forecasts for growth over the next five years to 2012; Highlights and reviews of FDA restrictions, government legislation, as well as discussions on fungal resistance and changes in consumer preferences, such as a greater demand for OTC medications and/or natural and alternative remedies; Presentation of new drug and patent applications, new methods of drug administration, drug discovery and development, and various clinical trials and applications; Profiles for important companies.

INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THIS STUDY; CONTRIBUTIONS TO THE STUDY AND FOR WHOM; SCOPE AND FORMAT; METHODOLOGY; INFORMATION SOURCES; ANALYST CREDENTIALS; RELATED BCC REPORTS; BCC ONLINE SERVICES; DISCLAIMER
SUMMARY: SUMMARY TABLE GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS); SUMMARY FIGURE GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
OVERVIEW: HISTORY AND CURRENT STATE OF ANTIMICROBIALS
TABLE 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY: TYPES OF ANTIMICROBIALS; BACTERIA; VIRUSES; PROTOZOA; FUNGI; DEFINITION OF THE INDUSTRY; CONCEPTS IN THE INDUSTRY; IMPORTANCE OF THE INDUSTRY; PRODUCT LIFE CYCLES
TABLE 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG: DEVELOPMENT OF ANTIFUNGALS; FUTURE DEVELOPMENTS; 2006 NEW DRUG ACTIVITY; 2005 NEW DRUG ACTIVITY; WITH AN EYE TOWARD THE FUTURE; TYPE OF APPLICATIONS: HUMAN HEALTHCARE, VETERINARY, AGRICULTURE, AND ENVIRONMENTAL; TYPE OF APPLICATIONS: HUMAN HEALTHCARE; HUMAN FUNGAL INFECTIONS; RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS
TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS: CANDIDIASIS; Cutaneous Candidiasis; Chronic Mucocutaneous Candidiasis; GI Tract Candidiasis; Respiratory Tract Candidiasis; Genitourinary Tract Candidiasis; Hepatosplenic Candidiasis; Systemic Candidiasis; Candidemia; Disseminated Candidiasis; ASPERGILLOSIS; BLASTOMYCOSIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DERMATOPHYTOSIS; HISTOPLASMOSIS; ONYCHOMYCOSIS; PARACOCCIDIOIDOMYCOSIS; PSEUDALLESCHERIASIS; SPOROTRICHOSIS; ZYGOMYCOSIS
TABLE 4 INCIDENCE OF COMMON FUNGAL DISEASES: HUMAN ANTIFUNGAL AGENTS
TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS): ECHINOCANDINS; ANTIMETABOLITES; AZOLES; POLYENES; OTHER
TABLE 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
TABLE 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
FIGURE 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
TABLE 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
TABLE 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
TABLE 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT: SIDE EFFECTS
TABLE 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS: OVER THE COUNTER ANTIFUNGAL PREPARATIONS
TABLE 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION: NATURAL ANTIFUNGAL COMPLEXES; Herbal Antifungal Agents
TABLE 13 COMMON HERBAL ANTIFUNGALS: Enzyme-Based Antifungal Agents
TABLE 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS: Homeopathic Antifungal Agents; LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS; SPECIMEN EXAMINATION; CULTURES; BLOOD SEROLOGY; ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS; CAM TESTING AND SPECIALIZED LABORATORIES; QUESTIONNAIRE FOR SYMPTOMS; FUNGAL RESISTANCE
TABLE 15 COMMON REASONS FOR FUNGAL RESISTANCE: STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY; VETERINARY ANTIFUNGAL SEGMENT; THE INDUSTRY; VETERINARY FUNGAL INFECTIONS; ASPERGILLOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOCOSIS; EPIZOOTIC LYMPHANGITIS UNIQUE TO HORSES; GEOTRICHOSIS; HISTOPLASMOSIS; HYALOHYPHOMYCOSIS; MYCETOMAS; NORTH AMERICAN BLASTOMYCOSIS; OOMYCOSIS; PAECILOMYCOSIS; PENNICILLIOSIS; PHAEOHYPHOMYCOSIS; RHINOSPORIDIOSIS; SPOROTRICHOSIS; ZYGOMYCOSIS; VETERINARY ANTIFUNGAL AGENTS; POLYENES; AZOLES; ANTIMETABOLITES; OTHER; Griseofulvin; Lufenuron
TABLE 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
TABLE 16 (CONTINUED)
TABLE 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS: VETERINARY BASED LABORATORY TESTS AND HISTOLOGY; AGRICULTURAL ANTIFUNGAL SEGMENT; THE INDUSTRY; GOVERNMENT REGULATIONS; AGRICULTURE ANTIFUNGALS: MECHANISMS OF ACTION; AGRICULTURAL PRODUCTS AND APPLICATIONS
TABLE 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH ¡Ý100,000 LBS APPLIED, 2002
TABLE 18 (CONTINUED)
TABLE 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
TABLE 20 ANTIFUNGAL USE BY CROP TYPE, 2002: AGRICULTURAL SIDE EFFECTS
TABLE 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
TABLE 21 (CONTINUED): AGRICULTURAL FUNGAL RESISTANCE; STRATEGIES TO PREVENT FUNGAL RESISTANCE IN AGRICULTURAL FUNGI; ENVIRONMENTAL ANTIFUNGAL SEGMENT; THE INDUSTRY; WHY ENVIRONMENTAL MOULD IS A UNIQUE PROBLEM; COMMON ENVIRONMENTAL MOULDS; ALTERNARIA; ASPERGILLUS; CLADOSPORIUM; PENICILLIUM; HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOULD
TABLE 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
TABLE 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
TABLE 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS: GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS; GOVERNMENT REGULATIONS; FOOD AND DRUG ADMINISTRATION
TABLE 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
TABLE 25 (CONTINUED): ENVIRONMENTAL PROTECTION AGENCY (EPA); UNITED STATED DEPARTMENT OF AGRICULTURE (USDA); FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS; PROFESSIONAL ASSOCIATIONS; MEDICAL AND VETERINARY ASSOCIATIONS; AGRICULTURAL ASSOCIATIONS; OTHER ENVIRONMENTAL ASSOCIATIONS; MAJOR ANTIFUNGAL MANUFACTURERS; HUMAN HEALTHCARE; PHARMACEUTICAL MANUFACTURERS
TABLE 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
TABLE 26 (CONTINUED)
FIGURE 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
TABLE 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006 ($ MILLION): MAJOR PHARMACEUTICAL MANUFACTURER PROFILES; Astellas; Barrier Therapeutics; Enzon Pharmaceuticals; Gilead Sciences, Inc; Medicis; Teva Pharmaceutical USA; Novartis; Pfizer, Inc; Schering-Plough Corp; SciClone Pharmaceuticals, Inc; Taro Pharmaceutical Industries, Ltd.; York Pharma; MAJOR OTC ANTIFUNGAL MANUFACTURERS; PHARMACEUTICAL OTC MARKET
TABLE 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS: PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES; Alva-Amco Pharmacal; Blaine Labs; Dartmouth Pharmaceuticals; Del Laboratories; Dermik; Ganeden Biotech; McNeil Consumer and Specialty Pharmaceuticals; Kramer Laboratories; Novartis; Pedinol Pharmacal; Pfizer; Schering-Plough; Stiefel Laboratories; Tarmac Products; ALTERNATIVE OTC MARKET
TABLE 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS: ProSymbiotics; Nature’s Plus; Aqua Flora; NOW Foods; Rainbow Light; Enzymedica; Pure Essence Laboratories; Michael’s Naturopathic Programs; Renew Life; Garden of Life; Nutrition Now; Solaray; Vitanica; Forest Herbs Research; Crystal Star Herbal Nutrition; VETERINARY MARKET
TABLE 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
TABLE 30 (CONTINUED)
FIGURE 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%): MAJOR VETERINARY ANTIFUNGAL MANUFACTURER PROFILES; Argent; Bioniche Life Science; Butler Animal Health; Durvet Animal Health Products; Med-Pharmex; Virbac; Schering-Plough Animal Health; Stiefel; Vetoquinol; Vedco; Wyeth Animal Health; AGRICULTURAL ANTIFUNGAL MANUFACTURERS
TABLE 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
FIGURE 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%): MAJOR AGRICULTURAL MANUFACTURER PROFILES; AgriChem; AgraQuest; Albaugh, Inc; American Vanguard; Arysta Life Sciences; BASF; Bayer CropScience; Makhteshim Agan of North America, Inc.; Cerexagri; Chemtura; Dow AgroSciences; DuPont Crop Protection; Gowan; JH Biotech; Helena Chemical Company; Nordox AS; Nufarm; Syngenta; Valent; ANTIFUNGAL INDUSTRY; ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE; ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT
TABLE 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
TABLE 33 NEW PRESCRIPTION ANTIFUNGALS, 2005-2006: INCREASED TYPES OF TESTING; Need to Increase Use and Acceptance of Newer Drugs; Trends in Class Used and Administration Method
TABLE 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
FIGURE 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
TABLE 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS): UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS; Shifting Market from Prescription to OTC
TABLE 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
TABLE 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS): Market Demand for OTC Products; ANTIFUNGAL MARKET TRENDS: VETERINARY HEALTH; ANTIFUNGAL MARKET TRENDS—AGRICULTURAL; DECREASE IN NUMBER OF MANUFACTURERS; DECREASE IN PRICE PER POUND OF SYNTHETIC AGENTS; INCREASED PRODUCTION AND DISTRIBUTION OF GENERICS; INCREASE IN FUNGAL RESISTANCE IN PHYTOMYCOTIC ORGANISMS; PATENT ANALYSIS; PURPOSE OF A PATENT ANALYSIS; DUE CARE IN REVIEWING THE PATENT ANALYSIS; NEW ANTIFUNGAL PATENTS ISSUED
TABLE 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
TABLE 38 (CONTINUED)
FIGURE 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
TABLE 39 PATENT BY ANTIFUNGAL MARKET SEGMENT, 1990-2006
TABLE 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
TABLE 40 (CONTINUED)
TABLE 40 (CONTINUED)
TABLE 40 (CONTINUED)
TABLE 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
TABLE 42 PATENT TRENDS BY COUNTRY, 2005-2006
FIGURE 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%): TRENDS IN PATENT APPLICATIONS
TABLE 43 PATENT APPLICATION TRENDS, 2001-2006
FIGURE 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
TABLE 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
FIGURE 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
TABLE 45 NEW PATENT APPLICATIONS, 2005-2006
TABLE 45 (CONTINUED)
TABLE 45 (CONTINUED)
TABLE 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
TABLE 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
FIGURE 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%): PATENT EXPIRATIONS
TABLE 48 PATENT EXPIRATIONS, 2006-2011: APPENDIX
TABLE 49 PHARMACEUTICAL COMPANIES
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
TABLE 49 (CONTINUED)
LIST OF TABLES: SUMMARY TABLE GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS)
TABLE 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY
TABLE 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
TABLE 4 INCIDENCE OF COMMON FUNGAL DISEASES
TABLE 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS)
TABLE 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
TABLE 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
TABLE 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
TABLE 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
TABLE 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
TABLE 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
TABLE 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
TABLE 13 COMMON HERBAL ANTIFUNGALS
TABLE 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS
TABLE 15 COMMON REASONS FOR FUNGAL RESISTANCE
TABLE 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
TABLE 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS
TABLE 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH ¡Ý100,000 LBS APPLIED, 2002
TABLE 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
TABLE 20 ANTIFUNGAL USE BY CROP TYPE, 2002
TABLE 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
TABLE 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
TABLE 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
TABLE 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS
TABLE 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
TABLE 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
TABLE 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006: ($ MILLION)
TABLE 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
TABLE 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
TABLE 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
TABLE 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
TABLE 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
TABLE 33 NEW PRESCRIPTION ANTIFUNGALS: 2005-2006
TABLE 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
TABLE 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS)
TABLE 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
TABLE 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS)
TABLE 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
TABLE 39 PATENT BY ANTIFUNGAL MARKET SEGMENT: 1990-2006
TABLE 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
TABLE 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
TABLE 42 PATENT TRENDS BY COUNTRY, 2005-2006
TABLE 43 PATENT APPLICATION TRENDS, 2001-2006
TABLE 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
TABLE 45 NEW PATENT APPLICATIONS, 2005-2006
TABLE 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
TABLE 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
TABLE 48 PATENT EXPIRATIONS, 2006-2011
TABLE 49 PHARMACEUTICAL COMPANIES
LIST OF FIGURES: SUMMARY FIGURE GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
FIGURE 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
FIGURE 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
FIGURE 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)
FIGURE 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)
FIGURE 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
FIGURE 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
FIGURE 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%)
FIGURE 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
FIGURE 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
FIGURE 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%)

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

Global Markets for Antifungal Agents

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service